There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Achieve Life Sciences (ACHV – Research Report), Aziyo Biologics (ELUT – Research Report) and Arcadia Biosciences (RKDA – Research Report) with bullish sentiments.
Achieve Life Sciences (ACHV)
Lake Street analyst Thomas Flaten maintained a Buy rating on Achieve Life Sciences today and set a price target of $11.00. The company’s shares closed last Thursday at $4.53.
According to TipRanks.com, Flaten ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Achieve Life Sciences with a $20.33 average price target, representing a 326.2% upside. In a report released today, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $30.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Aziyo Biologics (ELUT)
Lake Street analyst Frank Takkinen reiterated a Buy rating on Aziyo Biologics today and set a price target of $5.00. The company’s shares closed last Thursday at $2.80.
According to TipRanks.com, Takkinen has 0 stars on 0-5 stars ranking scale with an average return of
Aziyo Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, representing a 73.6% upside. In a report released today, Cantor Fitzgerald also maintained a Buy rating on the stock with a $5.00 price target.
Arcadia Biosciences (RKDA)
In a report released today, Ben Klieve from Lake Street maintained a Buy rating on Arcadia Biosciences, with a price target of $12.00. The company’s shares closed last Thursday at $2.08, close to its 52-week low of $1.85.
According to TipRanks.com, Klieve is ranked #970 out of 8834 analysts.
Currently, the analyst consensus on Arcadia Biosciences is a Moderate Buy with an average price target of $11.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ACHV:
- Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update
- ACHV Earnings this Week: How Will it Perform?
- Achieve Life Sciences announces publication of vaping cessation trial results
- Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine
- Achieve Life Sciences files to sell 13.09M shares of common stock for holders
